1
|
Carrizzo A, Basilicata MG, Pepe G, Sørensen KK, Ciccarelli M, Sarno VD, Damato A, Venturini E, Borrelli A, Musella S, Abate M, Pietro PD, Ostacolo C, Campiglia P, Vecchione C. A Novel Vasoactive Peptide "PG1" from Buffalo Ice-Cream Protects from Angiotensin-Evoked High Blood Pressure. Antioxidants (Basel) 2021; 10:antiox10030441. [PMID: 33809389 PMCID: PMC8002072 DOI: 10.3390/antiox10030441] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 02/24/2021] [Accepted: 03/08/2021] [Indexed: 12/22/2022] Open
Abstract
Background: Arterial hypertension is the most important risk factor for cardiovascular diseases, myocardial infarction, heart failure, renal failure and peripheral vascular disease. In the last decade, milk-derived bioactive peptides have attracted attention for their beneficial cardiovascular properties. Methods: Here, we combined in vitro chemical assay such as LC-MS/MS analysis of buffalo ice cream, ex vivo vascular studies evaluating endothelial and smooth muscle responses using pressure myograph, and translational assay testing in vivo the vascular actions of PG1 administration in murine models. Results: We demonstrate that a novel buffalo ice-cream-derived pentapeptide “QKEPM”, namely PG1, is a stable peptide that can be obtained at higher concentration after gastro-intestinal digestions (GID) of buffalo ice-cream (BIC). It owns potent vascular effect in counteract the effects of angiotensin II-evoked vasoconstriction and high blood pressure levels. Its effects are mediated by the inhibitory effect on AT1 receptor leading to a downregulation of p-ERK½/Rac1-GTP and consequent reduction of oxidative stress. Conclusions: These results strongly candidate PG1, as a novel bioactive peptide for the prevention and management of hypertension, thus expanding the armamentarium of preventive strategies aimed at reducing the incidence and progression of hypertension and its related cardiovascular complications.
Collapse
Affiliation(s)
- Albino Carrizzo
- Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy; (A.C.); (M.C.); (M.A.); (P.D.P.)
- IRCCS Neuromed, Vascular Pathophysiology Unit, 86077 Pozzilli, IS, Italy; (A.D.); (E.V.)
| | | | - Giacomo Pepe
- Department of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy; (M.G.B.); (G.P.); (V.D.S.)
| | - Kasper K. Sørensen
- Department of Chemistry, University of Copenhagen, 1870 Frederiksberg, Denmark;
- Biomolecular Nanoscale Engineering Center, University of Copenhagen, 1870 Frederiksberg, Denmark
| | - Michele Ciccarelli
- Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy; (A.C.); (M.C.); (M.A.); (P.D.P.)
| | - Veronica Di Sarno
- Department of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy; (M.G.B.); (G.P.); (V.D.S.)
| | - Antonio Damato
- IRCCS Neuromed, Vascular Pathophysiology Unit, 86077 Pozzilli, IS, Italy; (A.D.); (E.V.)
| | - Eleonora Venturini
- IRCCS Neuromed, Vascular Pathophysiology Unit, 86077 Pozzilli, IS, Italy; (A.D.); (E.V.)
| | - Anna Borrelli
- University Hospital “San Giovanni di Dio e Ruggi D’Aragona”, via S. Leonardo, 1, 84131 Salerno, SA, Italy;
| | - Simona Musella
- European Biomedical Research Institute of Salerno, 84131 Salerno, SA, Italy;
| | - Mario Abate
- Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy; (A.C.); (M.C.); (M.A.); (P.D.P.)
| | - Paola Di Pietro
- Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy; (A.C.); (M.C.); (M.A.); (P.D.P.)
| | - Carmine Ostacolo
- Department of Pharmacy, University of Naples Federico II, 80131 Napoli, NA, Italy;
| | - Pietro Campiglia
- Department of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy; (M.G.B.); (G.P.); (V.D.S.)
- Correspondence: (P.C.); (C.V.); Tel.: +39-089-969242 (P.C.); +39-08-996-5069 (C.V.)
| | - Carmine Vecchione
- Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy; (A.C.); (M.C.); (M.A.); (P.D.P.)
- IRCCS Neuromed, Vascular Pathophysiology Unit, 86077 Pozzilli, IS, Italy; (A.D.); (E.V.)
- Correspondence: (P.C.); (C.V.); Tel.: +39-089-969242 (P.C.); +39-08-996-5069 (C.V.)
| |
Collapse
|
7
|
Oliveira V, Akamine EH, Carvalho MHC, Michelini LC, Fortes ZB, Cunha TS, do Carmo Franco M. Influence of aerobic training on the reduced vasoconstriction to angiotensin II in rats exposed to intrauterine growth restriction: possible role of oxidative stress and AT2 receptor of angiotensin II. PLoS One 2014; 9:e113035. [PMID: 25406086 PMCID: PMC4236150 DOI: 10.1371/journal.pone.0113035] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2014] [Accepted: 07/21/2014] [Indexed: 12/31/2022] Open
Abstract
Intrauterine growth restriction (IUGR) is associated with impaired vascular function, which contributes to the increased incidence of chronic disease. The aim of this study was to investigate whether aerobic training improves AngII-induced vasoconstriction in IUGR rats. Moreover, we assess the role of superoxide dismutase (SOD) isoforms and NADPH oxidase-derived superoxide anions in this improvement. Female Wistar rats were randomly divided into two groups on day 1 of pregnancy. A control group was fed standard chow ad libitum, and a restricted group was fed 50% of the ad libitum intake throughout gestation. At 8 weeks of age, male offspring from both groups were randomly assigned to 4 experimental groups: sedentary control (SC), trained control (TC), sedentary restricted (SRT), and trained restricted (TRT). The training protocol was performed on a treadmill and consisted of a continuous 60-min session 5 days/week for 10 weeks. Following aerobic training, concentration–response curves to AngII were obtained in endothelium-intact aortic rings. Protein expression of SOD isoforms, AngII receptors and the NADPH oxidase component p47phox was assessed by Western blot analysis. The dihydroethidium was used to evaluate the in situ superoxide levels under basal conditions or in the presence of apocynin, losartan or PD 123,319. Our results indicate that aerobic training can prevent IUGR-associated increases in AngII-dependent vasoconstriction and can restore basal superoxide levels in the aortic rings of TRT rats. Moreover, we observed that aerobic training normalized the increased p47phox protein expression and increased MnSOD and AT2 receptor protein expression in thoracic aortas of SRT rats. In summary, aerobic training can result in an upregulation of antioxidant defense by improved of MnSOD expression and attenuation of NADPH oxidase component p47phox. These effects are accompanied by increased expression of AT2 receptor, which provide positive effects against Ang II–induced superoxide generation, resulting in attenuation of AngII-induced vasoconstriction.
Collapse
Affiliation(s)
- Vanessa Oliveira
- Nephrology Division, School of Medicine, Federal University of São Paulo, São Paulo, Brazil
| | | | | | | | | | - Tatiana Sousa Cunha
- Science and Technology Institute, Federal University of São Paulo, São Paulo, Brazil
| | - Maria do Carmo Franco
- Nephrology Division, School of Medicine, Federal University of São Paulo, São Paulo, Brazil
- Physiology Department, School of Medicine, Federal University of São Paulo, São Paulo, Brazil
- * E-mail:
| |
Collapse
|
8
|
Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, Tsukuda K, Chisaka T, Bai HY, Wang XL, Ogimoto A, Higaki J, Horiuchi M. Possible Role of Angiotensin-Converting Enzyme 2 and Activation of Angiotensin II Type 2 Receptor by Angiotensin-(1–7) in Improvement of Vascular Remodeling by Angiotensin II Type 1 Receptor Blockade. Hypertension 2014; 63:e53-9. [DOI: 10.1161/hypertensionaha.113.02426] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cross talk between the angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/Ang II type 1 (AT
1
) receptor axis and the ACE2/Ang-(1–7)/Mas axis plays a role in the pathogenesis of cardiovascular remodeling. Furthermore, possible stimulation of the Ang II type 2 (AT
2
) receptor by Ang-(1–7) has been highlighted as a new pathway. Therefore, we examined the possibility of whether the ACE2/Ang-(1–7)/Mas axis and Ang-(1–7)/AT
2
receptor axis are involved in the inhibitory effects of AT
1
receptor blockers on vascular remodeling. Wild-type, Mas-knockout, and AT
2
receptor knockout mice were used in this study. Vascular injury was induced by polyethylene-cuff placement around the mouse femoral artery. Some mice were treated with azilsartan, an AT
1
receptor blocker, or Ang-(1–7). Neointimal formation 2 weeks after cuff placement was more marked in Mas-knockout mice compared with wild-type mice. Treatment with azilsartan or Ang-(1–7) attenuated neointimal area, vascular smooth muscle cell proliferation, increases in the mRNA levels of monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin-1β, and superoxide anion production in the injured artery; however, these inhibitory effects of azilsartan and Ang-(1–7) were less marked in Mas-knockout mice. Administration of azilsartan or Ang-(1–7) attenuated the decrease in ACE2 mRNA and increased AT
2
receptor mRNA but did not affect AT
1
receptor mRNA or the decrease in Mas mRNA. The inhibitory effect of Ang-(1–7) on neointimal formation was less marked in AT
2
receptor knockout mice compared with wild-type mice. These results suggest that blockade of the AT
1
receptor by azilsartan could enhance the activities of the ACE2/Ang-(1–7)/Mas axis and ACE2/Ang-(1–7)/AT
2
receptor axis, thereby inhibiting neointimal formation.
Collapse
Affiliation(s)
- Kousei Ohshima
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Masaki Mogi
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Hirotomo Nakaoka
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Jun Iwanami
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Li-Juan Min
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Harumi Kanno
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Kana Tsukuda
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Toshiyuki Chisaka
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Hui-Yu Bai
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Xiao-Li Wang
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Akiyoshi Ogimoto
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Jitsuo Higaki
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| | - Masatsugu Horiuchi
- From the Departments of Molecular Cardiovascular Biology and Pharmacology (K.O., M.M., H.N., J.I., L.-J.M., H.K., K.T., H.-Y.B., X.-L.W., M.H.), Cardiology, Pulmonology, Hypertension and Nephrology (K.O., A.O., J.H.), and Pediatrics (T.C.), Ehime University, Graduate School of Medicine, Tohon, Ehime, Japan
| |
Collapse
|